@drsalaswhalen's HSDD and testosterone claims, fact-checked

What did @drsalaswhalen actually say?

The core claim here is straightforward: HSDD, hypoactive sexual desire disorder, is a clinical diagnosis, not a lab value. You don't need a low testosterone level to qualify. She described HSDD as requiring six months or more of low libido, absent sexual fantasies, reduced desire, and avoidance of sexual activity that causes personal or relationship distress. She also said testosterone therapy in this context aims for the "normal premenopausal range," citing reference ranges of 4 to 50 ng/dL depending on the lab, and warned that going above those ranges risks side effects like hair loss, acne, facial hair, and irritability.

That's a reasonably complete summary of how HSDD is actually defined and managed in clinical practice. The framing is accurate. The details are mostly accurate. But there's one consistent verbal slip worth flagging before we get into the science.

Does the science back this up?

Yes, largely. The claim that HSDD is a clinical diagnosis not contingent on a testosterone blood test is well-supported. The Endocrine Society's 2019 clinical practice guideline (Wierman et al., 2019, Journal of Clinical Endocrinology and Metabolism) explicitly states that a low serum testosterone level should not be required for diagnosis or treatment eligibility in women with sexual dysfunction. The diagnosis is based on symptoms and distress, not a number on a lab report.

On testosterone therapy itself, a 2019 international consensus position statement (Davis et al., 2019, Journal of Clinical Endocrinology and Metabolism) reviewed 36 randomized controlled trials and concluded that testosterone therapy significantly improves sexual function in postmenopausal women, including desire, arousal, and orgasm frequency, compared to placebo. The evidence base here is real, not speculative.

The reference ranges she cited, 4 to 50 ng/dL for Quest and LabCorp, are in the right ballpark for female testosterone reference ranges, though these vary enough by assay method that single-number cutoffs should be interpreted cautiously. That's a minor but real caveat she didn't address.

What did they get wrong (or right)?

She consistently said "hyperactive sexual desire disorder" throughout the video. The actual diagnosis is hypoactive, meaning abnormally low. Hyperactive would mean the opposite problem entirely. This is almost certainly a verbal slip rather than a conceptual error, since she described the symptoms correctly, but it's the kind of error that spreads fast on social media and could genuinely confuse someone newly researching the condition.

What she got right: the clinical framing is solid. The point that lab values alone don't determine treatment eligibility is not only accurate, it's a commonly misunderstood aspect of HSDD management. Many providers and patients assume a testosterone level must be "low" to justify therapy. The evidence does not support that gatekeeping. She also correctly identified that supraphysiologic testosterone levels, going above the normal female range, are associated with androgenic side effects. That's accurate and worth saying plainly.

One thing she didn't say: testosterone is not FDA-approved for HSDD in women in the US. The only approved drug for premenopausal HSDD is flibanserin (Addyi). Testosterone is used off-label for this indication. That context matters and was absent.

What should you actually know?

If you're experiencing low libido and a provider tells you your testosterone is "normal" so there's nothing to treat, that's incomplete reasoning. HSDD is diagnosed based on symptoms and distress, not a threshold on a blood test. The research supporting testosterone for sexual function in women, particularly postmenopausal women, is among the more robust in the hormone therapy literature.

However, testosterone therapy for women in the US operates in an off-label context. No FDA-approved female testosterone product exists in the US. That means dosing, formulation, and monitoring standards are less standardized than they would be for an approved indication. The reference ranges she cited are real, but female testosterone measurement has known reliability problems at low concentrations with standard immunoassay methods. Mass spectrometry-based testing is generally considered more accurate for women.

• HSDD requires symptoms lasting six months or more that cause personal or relational distress
• A normal testosterone level does not rule out HSDD or disqualify someone from testosterone therapy
• Davis et al. 2019 found significant improvement in sexual function across 36 RCTs
• Testosterone therapy for women is off-label in the US, which affects how it's regulated and monitored
• Going above the normal female testosterone range increases risk of androgenic side effects